Rapamycin Promotes Vascular Smooth Muscle Cell Differentiation Through Insulin Receptor Substrate-1/Phosphatidylinositol 3-Kinase/Akt2 Feedback Signaling

Research Summary

An experimental study on how rapamycin changes the behaviour of vascular smooth muscle cells (VSMCs) — the muscle cells in the wall of blood vessels. The authors report that rapamycin drives these cells toward a mature, contractile state, and trace the effect to a signalling route running through IRS-1, PI3K and one specific Akt isoform, Akt2.

Who Or What Was Studied?

Cultured human vascular smooth muscle cells, taken from vascular surgery patients and organ donors or bought as human coronary artery cells, together with bovine and rat aortic smooth muscle cells. Cells were grown in medium containing 2.5% serum or no serum and treated with rapamycin 20 nM, IGF-I, insulin or vehicle, with protein and RNA readouts taken over minutes to 48 hours.

What Did The Research Show?

• Rapamycin activated Akt (phosphorylation at serine 473) within 30 minutes and induced contractile proteins including smooth muscle myosin heavy chain and h-caldesmon, while completely blocking phosphorylation of ribosomal S6 — confirming that it hit its intended target S6K1.
• The effect needed serum or IGF-I: rapamycin did not activate Akt in serum-free medium, and blocking IGF-I with a neutralising antibody abolished rapamycin-induced Akt activation.
• Rapamycin reduced inhibitory serine phosphorylation of IRS-1, shifted IRS-1 to a form consistent with tyrosine phosphorylation, and promoted association of tyrosine-phosphorylated IRS-1 with the p85 subunit of PI3K.
• A rapamycin-resistant S6K1 mutant prevented rapamycin-induced Akt activation and contractile protein expression, indicating that relief of S6K1-mediated inhibition of IRS-1 is required.
• Rapamycin activated only the Akt2 isoform, not Akt1: Akt2 knockdown blocked rapamycin-induced differentiation, and overexpressing Akt2 (but not Akt1) was enough to induce contractile proteins.

Limitations And Interpretation

• Cell-culture work, not human outcomes: these results describe a signalling mechanism, not a clinical effect in patients.
• The study concerns vascular smooth muscle differentiation in vitro; no animals or people were treated with rapamycin here.
• The evidence comes largely from protein (Western blot) data in cultured cells, and the authors note S6K1 is likely to have other targets besides IRS-1.